DKK3 and malignant colon neoplasm: In fact, gene therapies delivering DKK3 and AXIN2, which were demonstrated to be targets of miR-582-3p in this study, are being clinically tested in prostate cancer and colon cancer, respectively (NCT01197209, NCT01882660).